Tiratricol
As of the edition of 20 October 2026, Tiratricol is a small molecule: marketed, first approved in 2025 (EU); acts on THRA and THRB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Emcitate
- First approved
- 12 February 2025 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Rare Thyroid Therapeutics
- Registered trials
- 4, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Rare Thyroid Therapeutics | Applicant and Lead sponsor of trials | 2025 to now |